Kanser Kök Hücre Hipotezi ve Tedavi Stratejilerindeki Önemi
Özet
Kanser kök hücresi (KKH) hipotezi, tümör heterojenliğini ve tedavi direncini açıklamada geleneksel mutasyonel modelin yetersizliklerine karşı güçlü bir alternatif sunmaktadır. İlk kez 1997'de lösemide tanımlanan KKH'ler; kendi kendini yenileme, farklılaşma ve uyuyan (sessiz) kalabilme gibi temel kök hücre özelliklerine sahiptir. Klasik hiyerarşik modelin aksine, güncel araştırmalar KKH'lerin esnek bir plastisiteye sahip olduğunu, farklılaşmış tümör hücrelerinin de çevresel uyaranlarla yeniden kök hücre niteliği kazanabildiğini (EMT süreçleri vb.) göstermektedir. Ayrıca bu hücrelerin hipoksik nişlerde seçici olarak zenginleştiği, değişken metabolik yolaklar (glikoliz veya OxPhos) kullandığı ve ABC pompa regülasyonları ile standart kemoterapi/radyoterapiye direnç göstererek nükse yol açtığı saptanmıştır. All-trans retinoik asit uygulamaları, LSD1 ve BMI1 gibi epigenetik baskılayıcıların inhibisyonu ile WNT sinyal yolağının bloke edilmesi gibi KKH'lerin uç farklılaşmasını veya niş fonksiyonlarını hedefleyen yeni nesil akıllı anti-KKH tedavi stratejileri, kanserin kesin çözümüne yönelik klinik çalışmalarda umut vaat etmektedir.
The cancer stem cell (CSC) hypothesis offers a strong alternative to the traditional mutational model in explaining tumor heterogeneity and treatment resistance. First identified in leukemia in 1997, CSCs possess fundamental stem cell properties such as self-renewal, differentiation, and the ability to remain quiescent. Contrary to the classical hierarchical model, current research demonstrates that CSCs exhibit flexible plasticity, allowing differentiated tumor cells to regain stemness through environmental stimuli like EMT processes. Furthermore, these cells selectively enrich in hypoxic niches, utilize variable metabolic pathways (glycolysis or OxPhos), and cause tumor relapse by displaying resistance to standard chemotherapy and radiotherapy via ABC pump regulations. Next-generation intelligent anti-CSC therapeutic strategies—targeting terminal differentiation or niche functions through all-trans retinoic acid applications, inhibition of epigenetic repressors like LSD1 and BMI1, and blockade of the WNT signaling pathway—show promise in clinical trials aimed at definitively curing cancer.
Referanslar
Clevers, H. The intestinal crypt, a prototype stem cell compartment. Cell 154, 274–284 (2013)..
Doulatov, S., Notta, F., Laurenti, E. & Dick, J.E. Hematopoiesis: a human perspective. Cell Stem Cell 10, 120–136 (2012).
Uckun, F.M. et al. Leukemic cell growth in SCID mice as a predictor of relapse in high-risk B-lineage acute lymphoblastic leukemia. Blood 85, 873–878 (1995).
Lapidot, T. et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID
Bonnet, D. & Dick, J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3, 730–737 (1997).
Conversion of Stem Cells to Cancer Stem Cells: Undercurrent of Cancer Initiation, Cancers 2019, 11(3), 345;
Ricci-Vitiani, L. et al. Identification and expansion of human colon-cancer-initiating cells. Nature 445, 111–115 (2007)
Driessens, G., Beck, B., Caauwe, A., Simons, B.D. & Blanpain, C. Defining the mode of tumour growth by clonal analysis. Nature 488, 527–530 (2012)
Schepers, A.G. et al. Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science 337, 730–735 (2012).
Kozar, S. et al. Continuous clonal labeling reveals small numbers of functional stem cells in intestinal crypts and adenomas. Cell Stem Cell 13, 626–633 (2013)
Zomer, A. et al. Intravital imaging of cancer stem cell plasticity in mammary tumors. Stem Cells 31, 602–606 (2013)
Tian, H. et al. A reserve stem cell population in small intestine renders Lgr5-positive cells dispensable. Nature 478, 255–259 (2011).
Chen, J. et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488, 522–526 (2012).
Oshimori, N., Oristian, D. & Fuchs, E. TGF-b promotes heterogeneity and drug resistance in squamous cell carcinoma. Cell 160, 963–976 (2015)
Clevers, H. STEM CELLS. What is an adult stem cell? Science 350, 1319–1320 (2015)
Barker, N., et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 449, 1003–1007 (2007).
Barker, N. et al. Lgr5(+ve) stem cells drive self-renewal in the stomach and build long-lived gastric units in vitro. Cell Stem Cell 6, 25–36 (2010)
Snippert, H.J. et al. Intestinal crypt homeostasis results from neutral competition between symmetrically dividing Lgr5 stem cells. Cell 143, 134–144 (2010)
Lopez-Garcia, C., Klein, A.M., Simons, B.D. & Winton, D.J. Intestinal stem cell replacement follows a pattern of neutral drift. Science 330, 822–825 (2010)
Quintana, E. et al. Efficient tumour formation by single human melanoma cells. Nature 456, 593–598 (2008).
Ball, C.R. et al. Succession of transiently active tumor-initiating cell clones in human pancreatic cancer xenografts. EMBO Mol. Med. 9, 918–932 (2017).
Batlle, E. et al. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat. Cell Biol. 2, 84–89 (2000).
Cano, A. et al. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat. Cell Biol. 2, 76–83 (2000).
Savagner, P., Yamada, K.M. & Thiery, J.P. The zinc-finger protein slug causes desmosome dissociation, an initial and necessary step for growth factor-induced epithelial-mesenchymal transition. J. Cell Biol. 137, 1403–1419 (1997)
Mani, S.A. et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704–715 (2008)
Morel, A.P. et al. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 3, e2888 (2008).
Puisieux, A., Brabletz, T. & Caramel, J. Oncogenic roles of EMT-inducing transcription factors. Nat. Cell Biol. 16, 488–494 (2014)
Tsai, J.H., Donaher, J.L., Murphy, D.A., Chau, S. & Yang, J. Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell 22, 725–736 (2012).
Ocaña, O.H. et al. Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell 22, 709–724 (2012)
Beerling, E. et al. Plasticity between epithelial and mesenchymal states unlinks EMT from metastasis-enhancing stem cell capacity. Cell Reports 14, 2281–2288 (2016).
Suda, T., Takubo, K. & Semenza, G.L. Metabolic regulation of hematopoietic stem cells in the hypoxic niche. Cell Stem Cell 9, 298–310 (2011).
Simsek, T. et al. The distinct metabolic profile of hematopoietic stem cells reflects their location in a hypoxic niche. Cell Stem Cell 7, 380–390 (2010).
Maryanovich, M. et al. An MTCH2 pathway repressing mitochondria metabolism regulates haematopoietic stem cell fate. Nat. Commun. 6, 7901 (2015)
Tothova, Z. et al. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell 128, 325–339 (2007)
Viale, A. et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature 514, 628–632 (2014)
Peiris-Pagès, M., Martinez-Outschoorn, U.E., Pestell, R.G., Sotgia, F. & Lisanti, M.P. Cancer stem cell metabolism. Breast Cancer Res. 18, 55 (2016).
Sancho, P., Barneda, D. & Heeschen, C. Hallmarks of cancer stem cell metabolism. Br. J. Cancer 114, 1305–1312 (2016).
Pascual, G. et al. Targeting metastasis-initiating cells through the fatty acid receptor CD36. Nature 541, 41–45 (2017)
Ye, H. et al. Leukemic stem cells evade chemotherapy by metabolic adaptation to an adipose tissue niche. Cell Stem Cell 19, 23–37 (2016)
Borst, P. Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what? Open Biol. 2, 120066 (2012).
Holohan, C., Van Schaeybroeck, S., Longley, D.B. & Johnston, P.G. Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer 13, 714–726 (2013)
Diehn, M. et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458, 780–783 (2009)
Li, X. et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J. Natl. Cancer Inst. 100, 672–679 (2008)
Bao, S. et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756–760 (2006).
Clarkson, B., et al. Studies of cellular proliferation in human leukemia .3. Behavior of leukemic cells in three adults with acute leukemia given continuous infusions of 3H-thymidine for 8 or 10 days. Cancer 25, 1237–1260 (1970).
Killmann, S.A., Cronkite, E.P., Robertson, J.S., Fliedner, T.M. & Bond, V.P. Estimation of phases of the life cycle of leukemic cells from labeling in human beings in vivo with tritiated thymidine. Lab. Invest. 12, 671–684 (1963
Clarkson, B.D. Review of recent studies of cellular proliferation in acute leukemia. Natl. Cancer Inst. Monogr. 30, 81–120 (1969)
Clarkson, B. The survival value of the dormant state in neoplastic and normal populations. in Control of Proliferation in Animal Cells. (eds. Clarkson, B., Baserga, R.) 945–972 (Cold Spring Harbor Laboratory, New York, NY, 1974)
Clarkson, B.D. & Fried, J. Changing concepts of treatment in acute leukemia. Med. Clin. North Am. 55, 561–600 (1971).
Cronkite, E.P. Acute leukemia: is there a relationship between cell growth kinetics and response to chemotherapy? Proc. Natl. Cancer Conf. 6, 113–117 (1970).
van Es, J.H. et al. Dll1+ secretory progenitor cells revert to stem cells upon crypt damage. Nat. Cell Biol. 14, 1099–1104 (2012).
Buczacki, S.J. et al. Intestinal label-retaining cells are secretory precursors expressing Lgr5. Nature 495, 65–69 (2013)
Stange, D.E. et al. Differentiated Troy+ chief cells act as reserve stem cells to generate all lineages of the stomach epithelium. Cell 155, 357–368 (2013)
Wei, L. et al. Inhibition of CDK4/6 protects against radiation-induced intestinal injury in mice. J. Clin. Invest. 126, 4076–4087 (2016)
Singh, S.K. et al. Identification of human brain tumour initiating cells. Nature 432, 396–401 (2004)
Harris, W.J. et al. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell 21, 473–487 (2012)
Kreso, A. et al. Self-renewal as a therapeutic target in human colorectal cancer. Nat. Med. 20, 29–36 (2014)
Reya, T. & Clevers, H. Wnt signalling in stem cells and cancer. Nature 434, 843–850 (2005).
Anastas, J.N. & Moon, R.T. WNT signalling pathways as therapeutic targets in cancer. Nat. Rev. Cancer 13, 11–26 (2013).
Tammela, T. et al. A Wnt-producing niche drives proliferative potential and progression in lung adenocarcinoma. Nature 545, 355–359 (2017)
McGranahan, N. & Swanton, C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell 168, 613–628 (2017).
de Sousa e Melo, F. et al. A distinct role for Lgr5+ stem cells in primary and metastatic colon cancer. Nature 543, 676–680 (2017)
Fumagalli, A. et al. Genetic dissection of colorectal cancer progression by orthotopic transplantation of engineered cancer organoids. Proc. Natl. Acad. Sci. USA 114, E2357–E2364 (2017)
Fujii, M. et al. A colorectal tumor organoid library demonstrates progressive loss of niche factor requirements during tumorigenesis. Cell Stem Cell 18, 827–838 (2016)
